These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35332446)

  • 1. Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies.
    Crook C; Zhang YH; Li D
    Drugs Aging; 2022 Apr; 39(4):257-269. PubMed ID: 35332446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
    Raj N; Reidy-Lagunes D
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
    Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
    Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
    Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
    Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in medical treatment for pancreatic neuroendocrine neoplasms.
    Li YL; Cheng ZX; Yu FH; Tian C; Tan HY
    World J Gastroenterol; 2022 May; 28(20):2163-2175. PubMed ID: 35721885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
    Bilici A
    Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
    Cho CM
    Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical management of gastrointestinal neuroendocrine tumors.
    Perez K; Chan J
    Curr Opin Endocrinol Diabetes Obes; 2022 Apr; 29(2):219-224. PubMed ID: 35045527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors.
    Ikeda M; Hijioka S; Ito T; Matsumoto S; Honma Y; Ueno M; Okano N; Aoki T; Furuse J
    Jpn J Clin Oncol; 2024 Aug; 54(8):880-886. PubMed ID: 38677983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
    Rodriguez-Freixinos V; Thawer A; Capdevila J; Ferone D; Singh S
    Curr Oncol Rep; 2021 May; 23(7):80. PubMed ID: 33937962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Caplin ME
    Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
    Yalcin S
    Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A; Bodoky G
    Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.
    Mazziotti G; Mosca A; Frara S; Vitale G; Giustina A
    Expert Opin Pharmacother; 2017 Nov; 18(16):1679-1689. PubMed ID: 29067877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.